Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study. presentation at Heart Failure 2021 Online Congress

Back

HFA Premium Access

Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 1

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor J. Garcia-Pinilla (Malaga, ES)

Event: Heart Failure 2021 Online Congress

Presentation

About the speaker

Doctor Jose Manuel Garcia-Pinilla

Virgin of Victory University Hospital, Malaga (Spain)

0 follower

9 more presentations in this session

Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure

Speaker: Doctor M. Oberoi (Sioux Falls, US)

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Speaker: Mr J. Yang (South San Francisco, US)

Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies

Speaker: Doctor K. Jering (Boston, US)

Access

Abstract

Slides

Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)

Speaker: Doctor J. Ezekowitz (Edmonton, CA)

Initiation of sacubitril/valsartan in patients with renal impairment early after acute decompensated heart failure in the TRANSITION study

Speaker: Professor E. Straburzynska-Migaj (Poznan, PL)

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 1

Speakers: Doctor J. Garcia-Pinilla, Doctor M. Oberoi, Mr J. Yang, Doctor K. Jering, Doctor J. Ezekowitz...

Access

About the event

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Congress

Case report on a transthyretin-related amyloidosis caused by Leu32Val mutation and its interdisciplinary challenge.

27 August 2021

ESC Premium Access

Estimating treatment effect of tafamidis on hospitalisation in NYHA class III ATTR-CM patients in the presence of death using principal stratification

27 August 2021

ESC Premium Access

Exploration of electrocardiographic and echocardiographic findings to screen transthyretin amyloid cardiomyopathy in patients with mild left ventricular hypertrophy

27 August 2021

Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.

About the speaker

Doctor Jose Manuel Garcia-Pinilla

9 more presentations in this session

Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies

Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)

Initiation of sacubitril/valsartan in patients with renal impairment early after acute decompensated heart failure in the TRANSITION study

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 1

About the event

Heart Failure 2021 Online Congress

Related content

Case report on a transthyretin-related amyloidosis caused by Leu32Val mutation and its interdisciplinary challenge.

Estimating treatment effect of tafamidis on hospitalisation in NYHA class III ATTR-CM patients in the presence of death using principal stratification

Exploration of electrocardiographic and echocardiographic findings to screen transthyretin amyloid cardiomyopathy in patients with mild left ventricular hypertrophy

This platform is supported by